With our technology platform, we are able to develop a pipeline that target different growth factors to treat different solid tumours
We design synthetic therapeutics that include immunogenic sequence of growth factors domain that express with a synthetic carrier
We develop biologics that include growth factor domain(s) and an immunogenic carrier.
In3Bio’s innovative approach allows us to develop novel mono- or bi-specific therapeutics, in order to treat cancers which are often controlled by multiple growth factor-triggered pathways.
Our broad portfolio contains engineered synthetic growth factors; their natural counterparts playing crucial roles in tumour signalling pathways and (thereby) drug resistance modulation. Our pipeline covers a broad selection of candidates, each targeting major and multiple indications.
Together with other approved agents, in particular various small-molecule inhibitors used in precision-medicine directed targeted therapy, our pipeline includes combinations that have demonstrated significant potential in established pre-clinical models.